Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Clinical Investigation

• Publication date

  2004-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI20911PMID 15173883PMCID PMC419489
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.

  2004cited by this paper
• Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis.

  2004cited by this paper
• Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice

  2003cited by this paper
• Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

  2003cited by this paper
• β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

  2003cited by this paper
• Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis.

  2003cited by this paper
• Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased alpha-cell proliferation, and islet neogenesis.

  2003cited by this paper
• Intra-islet somatostatin regulates glucagon release via type 2 somatostatin receptors in rats.

  2003cited by this paper
• Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

  2003cited by this paper
• Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.

  2002cited by this paper
• Glycemic control in mice with targeted disruption of the glucagon receptor gene.

  2002cited by this paper
• Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats.

  2002cited by this paper
• Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy.

  2001cited by this paper
• Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.

  2001cited by this paper
• Effects of a novel glucagon receptor antagonist (Bay 27–9955) on glucagon-stimulated glucose production in humans

  2001cited by this paper
• Minireview: the glucagon-like peptides.

  2001cited by this paper
• The Glucagonoma Syndrome: A Review of its Features and Discussion of New Perspectives

  2001cited by this paper
• Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

  2001cited by this paper
• Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

  2000cited by this paper
• Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis

  2000cited by this paper
• Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state.

  2000cited by this paper
• Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats.

  2000cited by this paper
• Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression*

  1999cited by this paper
• Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets.

  1996cited by this paper
• Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits

  1996cited by this paper
• Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists.

  1996cited by this paper
• In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.

  1995cited by this paper
• Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats

  1994cited by this paper
• Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas.

  1990cited by this paper
• Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist.

  1989cited by this paper
• Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.

  1987cited by this paper
• Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.

  1985cited by this paper
• Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist.

  1982cited by this paper
• Letter: Glucagon in pathogenesis of diabetes.

  1975cited by this paper
• Glucagon in pathogenesis of diabetes

  1975cited by this paper

• TRPM7 kinase regulates α-cell proliferation and glucagon production in mice

  2026cites this paper
• Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference

  2025cites this paper
• A new link between insulinoma and congenital glucose-galactose malabsorption

  2025cites this paper
• Glucagon like peptide-1 modulates urinary sodium excretion in diabetic kidney disease via ENaC activation

  2025cites this paper
• Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence

  2024cites this paper
• Glucagon-based therapy for people with diabetes and obesity: what is the sweet spot?

  2024cites this paper
• Hepatic Glucagon Action - Beyond Glucose Mobilization.

  2024cites this paper
• The impact of glucagon to support postabsorptive glucose flux and glycemia in healthy rats and its attenuation in male Zucker diabetic fatty rats

  2024cites this paper
• Impaired Fat Absorption from Intestinal Tract in High-Fat Diet Fed Male Mice Deficient in Proglucagon-Derived Peptides

  2024cites this paper
• The human α cell in health and disease.

  2023cites this paper
• Gut hormone co-agonists for the treatment of obesity: from bench to bedside

  2023cites this paper
• Blockade of glucagon increases muscle mass and alters fiber type composition in mice deficient in proglucagon‐derived peptides

  2023cites this paper
• The uninhibited glucagon signaling pathway in Japanese flounder Paralichthys olivaceus: A link with the glucose intolerance?

  2023cites this paper
• Single-molecule analysis reveals that a glucagon-bound extracellular domain of the glucagon receptor is dynamic

  2023cites this paper
• Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.

  2022cites this paper
• The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease

  2022cites this paper
• Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes

  2022cites this paper
• Antisense oligonucleotides: recent progress in the treatment of various diseases

  2022cites this paper
• G protein-coupled receptor 151 regulates glucose metabolism and hepatic gluconeogenesis

  2022cites this paper
• Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?

  2022cites this paper
• γ-aminobutyric acid modulates α-cell hyperplasia but not β-cell regeneration induced by glucagon receptor antagonism in type 1 diabetic mice

  2022cites this paper
• High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides

  2022cites this paper
• Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice

  2022cites this paper
• Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes

  2022cites this paper
• Preclinical exploration of combined glucagon inhibition and liver-preferential insulin for treatment of diabetes using in vitro assays and rat and mouse models

  2022cites this paper
• Insights into the Role of Glucagon Receptor Signaling in Metabolic Regulation from Pharmacological Inhibition and Tissue-Specific Knockout Models

  2022cites this paper
• Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion

  2022cites this paper
• Perinatal exposure to chlorpyrifos and/or a high-fat diet is associated with liver damage in male rat offspring.

  2021cites this paper
• Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion.

  2021cites this paper
• AVP-induced counter-regulatory glucagon is diminished in type 1 diabetes

  2020cites this paper
• Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes

  2020influential citation
• Glucagon stimulates gluconeogenesis by InsP3R-I mediated hepatic lipolysis

  2020cites this paper
• Molecular cloning, sequence characteristics, and tissue expression analysis of glucagon receptor gene in Bama minipig

  2020cites this paper
• Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists

  2020cites this paper
• The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition

  2020cites this paper
• Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study

  2019cites this paper
• Glucagon Receptor Signaling and Lipid Metabolism

  2019cites this paper
• Glucagon receptor antagonism increases mouse pancreatic δ-cell mass through cell proliferation and duct-derived neogenesis.

  2019cites this paper
• A Primary Role for α-Cells as Amino Acid Sensors

  2019cites this paper
• Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy

  2019cites this paper
• Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice

  2019cites this paper
• Glucagon Receptor Signaling and Glucagon Resistance

  2019cites this paper
• Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives

  2019cites this paper
• Universitet Glucagon Receptor Signaling and Lipid Metabolism

  2019cites this paper
• Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity

  2019cites this paper
• Regulation of amino acid metabolism and α‐cell proliferation by glucagon

  2018cites this paper
• Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia

  2018cites this paper
• Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors)

  2018cites this paper
• The current state of GPCR‐based drug discovery to treat metabolic disease

  2018cites this paper
• SIRT1 activation attenuates α cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice

  2018cites this paper
• The New Biology and Pharmacology of Glucagon.

  2017cites this paper
• Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

  2017cites this paper
• Insulin and Glucagon: Partners for Life

  2017cites this paper
• Tumor Necrosis Factor-α Promotes Phosphoinositide 3-Kinase Enhancer A and AMP-Activated Protein Kinase Interaction to Suppress Lipid Oxidation in Skeletal Muscle

  2017cites this paper
• Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX

  2017cites this paper
• Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition

  2017cites this paper
• Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

  2017cites this paper
• Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes

  2017influential citation
• Hypoglycemic Effect of Combined Ghrelin and Glucagon Receptor Blockade

  2017cites this paper
• Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.

  2017cites this paper
• Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model

  2017cites this paper
• GLP-1/glucagon receptor co-agonism for treatment of obesity

  2017cites this paper
• Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist

  2016cites this paper
• THE ROLE OF GLUCAGON IN THE PATHOPHYSIOLOGY AND MANAGEMENT OF DIABETES.

  2016cites this paper
• Novel approaches to treating type 2 diabetes

  2016cites this paper
• Chapter 34 – Glucagon and the Glucagon-Like Peptides

  2016cites this paper
• An AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production

  2016cites this paper
• Effects of multiple ascending doses of the glucagon receptor antagonist PF‐06291874 in patients with type 2 diabetes mellitus

  2016cites this paper
• Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin

  2016cites this paper
• A synopsis of factors regulating beta cell development and beta cell mass

  2016cites this paper
• Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus

  2016cites this paper
• Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

  2015cites this paper
• Physiological and pathophysiological control of glucagon secretion by pancreatic α-cells

  2015cites this paper
• Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass.

  2015cites this paper
• Small molecule glucagon receptor antagonists: a patent review (2011 – 2014)

  2015cites this paper
• Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.

  2015cites this paper
• Islet α cells and glucagon—critical regulators of energy homeostasis

  2015cites this paper
• Benzimidazole Derivatives as Antidiabetic Agents

  2015cites this paper
• Inhibiting or antagonizing glucagon: making progress in diabetes care

  2015cites this paper
• Treatment of Obese Insulin-Resistant Mice With an Allosteric MAPKAPK2/3 Inhibitor Lowers Blood Glucose and Improves Insulin Sensitivity

  2015cites this paper
• First proof of pharmacology in humans of a novel glucagon receptor antisense drug

  2015cites this paper
• Evolving function and potential of pancreatic alpha cells.

  2015cites this paper
• Exploring the role of glucagon in glucose homeostasis

  2015cites this paper
• Lack of glucagon receptor signaling and its implications beyond glucose homeostasis.

  2015cites this paper
• Antisense Therapy for Cardiovascular Diseases.

  2015cites this paper
• Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

  2015cites this paper
• A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design

  2014cites this paper
• Recent Progress in the Use of Glucagon and Glucagon Receptor Antago-nists in the Treatment of Diabetes Mellitus

  2014cites this paper
• Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

  2014cites this paper
• New perspectives of vesicular monoamine transporter 2 chemical characteristics in mammals and its constant expression in type 1 diabetes rat models.

  2014cites this paper
• Blockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects

  2014cites this paper
• Energy metabolism in the liver.

  2014cites this paper
• Islets of Langerhans from prohormone convertase‐2 knockout mice show α‐cell hyperplasia and tumorigenesis with elevated α‐cell neogenesis

  2014cites this paper
• From Beta Cell Replacement to Beta Cell Regeneration

  2014cites this paper
• Nutrient regulation of glucagon secretion: involvement in metabolism and diabetes

  2014cites this paper
• FOLLOW-UP OF METABOLIC EFFECTS INDUCED BY A HIGH-FAT DIET AND STREPTOZOTOCIN IN A RODENT MODEL OF TYPE 2 DIABETES MELLITUS

  2014cites this paper
• Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production

  2014cites this paper
• Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice.

  2014cites this paper
• Regulation of alpha cell function by gp130 receptor signalling in a rodent model of type 2 diabetes

  2014cites this paper
• Pancreatic α-cell hyperplasia: facts and myths.

  2014cites this paper